Feb 16, 2023 02:00 PM Eastern Time (US and Canada)
We have often grappled with how to assess “acceptability” of HIV prevention interventions in our own studies.
The HIV literature offers varied approaches to conceptualize and measure acceptability, with many studies considering constructs like “intervention retention” or “product uptake” as sole acceptability indicators. However, acceptability is multi-faceted and separate from these behavioral outcomes. This presentation will describe findings from our recent systematic review, in which we inventory acceptability measurement in the HIV treatment and prevention literature (including biomedical, behavioral, and combination prevention approaches) and offer suggested rankings of these measures based on theoretical underpinnings and data collection approaches. We will conclude by sharing our recommendations for best practices in acceptability research, which are timely and critical in this era of informed choice and novel HIV prevention and treatment options.
Dr. Ortblad is an Assistant Professor at the Fred Hutchinson Cancer Center. Her research seeks to improve equity in health access with differentiated models of HIV service delivery in high prevalence settings, working in close collaboration with researchers from those settings. Her current NIH- and BMGF-funded projects, all in Kenya, include a randomized trial that explores the use of HIV self-testing (HIVST) to decrease the number of PrEP clinic visits, a study to design and test a novel model of pharmacy-based PrEP delivery, and a study to design and test a peer PrEP referral + HIVST delivery model to increase PrEP uptake and continuation among young women. She uses diverse research methods across the fields of epidemiology, economics, public policy, psychology, and implementation science.
Dr. Velloza is an Assistant Professor in the Division of Global Health and Infectious Disease Epidemiology at UCSF. Her research, teaching, and mentoring focus on advancing the field of global mental health and the intersection with HIV and STI prevention, specifically for adolescent girls and young women. In her current NIH-funded projects, Dr. Velloza uses implementation science, epidemiology, and behavioral science methods to design, evaluate, and scale-up integrated psychotherapy and HIV pre-exposure prophylaxis (PrEP) delivery models. She collaborates primilary with teams in South Africa and Kenya for this work. Dr. Velloza is also the Associate Program Director for Curriculum for the UCSF Implementation Science Training Program and is a faculty member with the UCSF Partnerships for Research in Implementation Science for Equity (PRISE) Center.
Join ZoomGov Meeting: